CRISPR Therapeutics
CRSP • NASDAQ
CRISPR Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Samarth Kulkarni, with a market cap of $4.4B.
CEOSamarth Kulkarni
Market Cap$4.4B
Biotechnology
Healthcare
Employees407.0
Websitecrisprtx.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for CRISPR Therapeutics
Date
Tuesday, May 5, 2026 (in 3 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.11
Revenue Estimate
$2.6M
Earnings History
Past 11 earnings reports for CRISPR Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2025 | Q3 2025 | -$1.17Est: -$1.30 | +10.0% | $889.0KEst: $8.1M | -89.0% |  10-Q |
| Aug 4, 2025 | Q2 2025 | -$1.29Est: -$1.43 | +9.8% | $892.0KEst: $6.5M | -86.3% | 10-Q |
| May 6, 2025 | Q1 2025 | -$1.58Est: -$1.25 | -26.4% | $865.0KEst: $6.4M | -86.5% | 10-Q |
| Feb 11, 2025 | Q4 2024 | -$0.44Est: -$1.21 | +63.6% | $35.7MEst: $7.4M | +383.6% | 10-K |
| Nov 5, 2024 | Q3 2024 | -$1.01Est: -$1.42 | +28.9% | $602.0KEst: $6.8M | -91.2% | 10-Q |
| Aug 5, 2024 | Q2 2024 | -$1.49Est: -$1.52 | +2.0% | $517.0KEst: $3.5M | -85.4% | 10-Q |
| May 8, 2024 | Q1 2024 | -$1.43Est: -$1.42 | -0.7% | $504.0KEst: $28.1M | -98.2% | 10-Q |
| Feb 21, 2024 | Q4 2023 | $1.10Est: -$0.07 | +1671.4% | $201.2MEst: $131.6M | +52.9% | 10-K |
| Nov 6, 2023 | Q3 2023 | -$1.41Est: -$1.96 | +28.1% | -Est: $8.4M | -100.0% | — |
| Aug 7, 2023 | Q2 2023 | -$0.98Est: -$2.12 | +53.8% | $70.0MEst: $1.7M | +3993.6% | 10-Q |
| May 8, 2023 | Q1 2023 | -$0.67Est: -$1.70 | +60.6% | $100.0MEst: $23.0M | +335.2% | 10-Q |